Mydran
Generic Name
Mydran-002-031
Manufacturer
Axiom Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| mydran 002 031 injection | ৳ 200.00 | N/A |
Description
Overview of the medicine
Mydran-002-031 is a broad-spectrum antibiotic from the cephalosporin class, effective against a wide range of bacterial infections. It is administered via injection.
Uses & Indications
Dosage
Adults
1-2 grams daily, administered as a single dose or in two divided doses. Max 4 grams/day.
Elderly
No specific dosage adjustment needed unless severe renal or hepatic impairment is present.
Renal_impairment
Dosage adjustment is necessary for severe renal impairment (CrCl < 10 mL/min). Consult physician.
How to Take
For IM administration, inject deeply into a large muscle mass. For IV administration, administer slowly over 2-4 minutes (bolus) or 30 minutes (infusion).
Mechanism of Action
Mydran-002-031 inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell lysis and death.
Pharmacokinetics
Onset
Within 30 minutes for intravenous administration.
Excretion
Primarily excreted unchanged via renal (glomerular filtration and tubular secretion) and biliary routes.
Half life
Approximately 6-9 hours.
Absorption
Rapidly and completely absorbed after intramuscular (IM) or intravenous (IV) administration.
Metabolism
Limited hepatic metabolism; a significant portion is metabolized in the intestine.
Side Effects
Contraindications
- Hypersensitivity to cephalosporins or any component of the formulation
- History of severe hypersensitivity to penicillin
Drug Interactions
Aminoglycosides
Increased risk of nephrotoxicity when co-administered.
Oral Anticoagulants (e.g., Warfarin)
May increase the anticoagulant effect, requiring close monitoring of INR.
Storage
Store below 30°C. Protect from light and moisture. Do not freeze. Reconstituted solution should be used immediately.
Overdose
Overdose symptoms may include nausea, vomiting, diarrhea, and convulsions. Management is primarily supportive, including hemodialysis if severe renal impairment.
Pregnancy & Lactation
Use in pregnancy only if clearly needed. Excreted in breast milk in small amounts; use with caution during lactation. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
Approved by DGDA
Patent Status
Generic available
WHO Essential Medicine
YesClinical Trials
Currently undergoing Phase III clinical trials for expanded indications in severe pediatric infections.
Lab Monitoring
- Renal function tests (e.g., creatinine, BUN) for prolonged therapy
- Liver function tests (LFTs) periodically
- Complete blood count (CBC) for long-term use
Doctor Notes
- Perform sensitivity testing prior to initiation of therapy.
- Monitor renal and hepatic function, especially in patients with pre-existing impairment or during prolonged therapy.
- Advise patients on potential for C. difficile infection if prolonged diarrhea occurs.
Patient Guidelines
- Complete the full course of treatment as prescribed, even if symptoms improve.
- Report any unusual or severe side effects to your doctor immediately.
- Do not share this medicine with others.
Missed Dose Advice
If a dose is missed, administer it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose.
Driving Precautions
Generally no effect on driving or operating machinery. However, if dizziness occurs, avoid such activities.
Lifestyle Advice
- Maintain good hydration during treatment.
- Rest sufficiently to aid recovery.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.